Bruton tyrosine kinase inhibitors and cardiovascular adverse events
British Journal of Pharmacology · 2026-07-30
DOI: 10.1111/bph.70620 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-07-30. Written by Massimiliano Camilli and 4 co-authors. Institution: Department of Cardiovascular Sciences, A. Gemelli University Policlinic Foundation IRCCS, Rome, Italy. Cited 1 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0).
Topics: Patientensicherheit
Abstract (original language)
Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias). Pharmacological differences in cardiotoxicity arise from binding mode and kinase selectivity profiles. First‐ and second‐generation covalent BTKi (ibrutinib, acalabrutinib, zanubrutinib) irreversibly target Cys481, leading to off‐target engagement of other kinases that regulate cardiac electrophysiology and also express homologous cysteine residues. In contrast, non‐covalent BTKi, such as pirtobrutinib, achieve selective and persistent BTK occupancy through Cys481‐independent interactions, substantially attenuating off‐target kinase inhibition and associated cardiotoxicity. Mechanistic insights support proactive baseline cardiovascular risk assessment and structured longitudinal surveillance to enable early detection, risk‐adapted management and sustained BTKi therapy. This mini‐review describes how such concepts apply to the issue of BTKi‐associated cardiovascular adverse events.
Subjects
Author keywords
Authors and institutions
- Department of Cardiovascular Sciences, A. Gemelli University Policlinic Foundation IRCCS, Rome, Italy.
- Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy.
- Department of Medicine, University Campus Bio-Medico, Rome, Italy.
- Department of Medicine and Department of Science and Biotechnology, University and Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Cite
APA
Camilli, M., Madaudo, C., Salvatorelli, E., Minotti, G., & Menna, P. (2026). Bruton tyrosine kinase inhibitors and cardiovascular adverse events. British Journal of Pharmacology. https://doi.org/10.1111/bph.70620
Vancouver
Camilli M, Madaudo C, Salvatorelli E, Minotti G, Menna P. Bruton tyrosine kinase inhibitors and cardiovascular adverse events. British Journal of Pharmacology. 2026. doi:10.1111/bph.70620
BibTeX
@article{Camilli2026,
author = {Camilli, Massimiliano and Madaudo, Cristina and Salvatorelli, Emanuela and Minotti, Giorgio and Menna, Pierantonio},
title = {Bruton tyrosine kinase inhibitors and cardiovascular adverse events},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70620}
}
EUVIMED